HIGHER VS STANDARD ADALIMUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 SERENE-UC JAPAN STUDY

S. Tanida  ¹     Y. Okuyama  ²     M. Watanabe  ³     T. HIBI  ⁴     K. Kobayashi  ⁵     T. Doan  ⁶     K. Ikeda  ⁶     B. Huang  ⁶     J. Petersson  ⁶     J. Kalabic  ⁷     A.M Robinson  ⁷     J. Panés  ^8    
1 Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
² Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
³ Advanced Research Institute and Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan
⁴ Center for Advanced Inflammatory Bowel Disease Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
⁵ AbbVie GK, Minato-ku, Tokyo, Japan
⁶ AbbVie Inc., North Chicago, IL, United States
⁷ AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
⁸ Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

Topic
IBD, Immunology

Session
IBD: Clinical trials I

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)